Bruce Trapnell
Director · Cincinnati Children's Hospital Medical Center
Credentials: · · · · ·
History
- 1990–1992
Pulmonary Disease
1976–1980
Research
Cell · 1992 · 900 citations
Efficacy and safety of sirolimus in lymphangioleiomyomatosis
New England Journal of Medicine · 2011 · 858 citations
Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy
Journal of Virology · 1996 · Last of 3 authors · 708 citations
27 papers
- CM
20 papers
19 papers
15 papers
10 papers
8 papers
- MB
7 papers
7 papers
Grants
- 2026–2031
Clinical Trial Readiness for Rare Lung Diseases
National Heart, Lung, and Blood Institute · U54
PI · $1.8M · University of Cincinnati
- 1995–2030
Interdisciplinary Training in Genome Sciences
National Human Genome Research Institute · T32
Contact PI · $4.5M · University of Washington
- 2019–2029
Technology to Understand Genetic Variant Effects in Context
National Human Genome Research Institute · RM1
PI · $6.4M · University of Washington
- 2019–2028
Versatile, Exponentially Scalable Methods for Single Cell Molecular Profiling
National Human Genome Research Institute · R01
PI · $5.9M · University of Washington
Clinical trials
- 2021–2027
Principal investigator · Active not recruiting · Phase 3
Savara Inc.
- 2012–2014
Principal investigator · Completed · Phase 2
Children's Hospital Medical Center, Cincinnati
- 2010–2015
Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency
Principal investigator · Completed · Phase 2
Beacon Therapeutics
- 2008–2010
Principal investigator · Completed · Phase 2
Gilead Sciences